NextCell Pharma AB (65G.F)

0.1500 -0.0045 (-2.91%) As of 11:38AM CEST. Market open.

NextCell Pharma AB

Karolinska Institutet Science Park
Hälsovägen 7
Huddinge 141 57
Sweden
46 87 35 55 95
https://www.nextcellpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mathias Svahn Ph.D.	Founder & CEO	983.53k	N/A	1976
Mr. Anders Essen-Möller M.Sc.	Chairman	N/A	N/A	1941
Mr. Patrik Fagerholm	Chief Financial Officer	N/A	N/A	1967
Mr. Lindsay Davies	Chief Scientific Officer	N/A	N/A	1979
Mr. Edvard Smith	Medical Director & Director	N/A	N/A	1951
Sofie Falk Jansson	Head of Cellaviva	N/A	N/A	1986
Ms. Karin Gillner	Head of Quality Assurance	N/A	N/A	1978
Ms. Sofia Sisay	Head of Clinical Trials	N/A	N/A	1981
Tacha Zi Plum Forshell	Head of GMP Facility	N/A	N/A	1977

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.

Corporate governance

NextCell Pharma AB’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.